Latest:
Dr. Thompson on Sequencing Strategies in HER2+ Breast Cancer
Forrest Thompson, MD, discusses sequencing strategies in HER2-positive breast cancer.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Frances Valdes-Albini, MD
Latest:
Dr. Valdes-Albini Discusses Trials in HER2+ Breast Cancer
Frances Valdes-Albini, MD, assistant professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses ongoing clinical trials of patients with HER2-positive breast cancer.
Francis J. Giles, MD
Latest:
ASH Interview Series
The December issue of Oncology & Biotech News featured highlights from the 51st American Society of Hematology (ASH) Annual Meeting and Exposition. We wrap up our ASH coverage this month with interviews on multiple myeloma with Brian G.M. Durie, MD, medical director and co-founder of the International Myeloma Foundation; chronic lymphocytic leukemia (CLL) with Robert J. Kreitman, MD, from the National Cancer Institute; and chronic myeloid leukemia (CML) with Francis J. Giles, MD, Cancer Therapy and Research Center at The University of Texas Health Science Center in San Antonio.
Francis Paul Worden, MD, University of Michigan Comprehensive Cancer Center
Latest:
Future Considerations for the Treatment of R/M HPV-Positive HNSCC
Panelists discuss how emerging areas in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) research include novel immunotherapy combinations, biomarker development for treatment selection, targeted therapies against new molecular pathways, and strategies to overcome resistance to existing treatments.
Francis Yao, MD
Latest:
Dr. Yao on Transplants Beyond Milan Criteria for Liver Cancer
Francis Yao, MD, gastroenterologist and medical director of the Liver Transplant Program at the University of California San Francisco Medical Center, discusses liver transplants beyond Milan criteria for patients with liver cancer.
Francisco Esteva, MD, PhD
Latest:
Dr Esteva on the Impact of the MAINTAIN Trial in HR+/HER2– Breast Cancer
Francisco J. Esteva, MD, PhD, discusses the impact of the phase 2 MAINTAIN study of treatment with ribociclib following progression on CDK4/6 inhibition in patients with hormone receptor-positive, HER2-negative breast cancer.